FDA approves first therapy for Sanfilippo Type A

On 17 September 2026, the FDA granted standard full approval to FAYUVI (rebisufligene etisparvovec-hopf), a single-dose intravenous AAV9 gene therapy from Ultragenyx, for pediatric patients with MPS IIIA, or Sanfilippo syndrome Type A. It is the first approved treatment for a fatal, ultra-rare neurodegenerative disease that previously had none. Sanfilippo Type A is caused by deficiency of the sulfamidase (SGSH) enzyme, which drives heparan sulfate accumulation and progressive damage to the central nervous system from early childhood. Median life expectancy is about 15 years, and an estimated 3,000 to 5,000 patients live in commercially accessible geographies.

One detail in the label determines who can benefit. FAYUVI is indicated for the neurologic manifestations of MPS IIIA in pediatric patients with preserved neurodevelopmental function. Because the underlying neurodegeneration is irreversible, a one-time therapy reaches its potential only in children who are identified, genetically confirmed, and treated before that decline takes hold. The molecule is the same for every eligible child; the outcome depends on timing.

An approval built on external natural-history data

The evidence base is as instructive as the result. Efficacy was established through the Transpher A trial, with long-term follow-up extending to nearly eight years. With no placebo arm feasible in a fatal pediatric disease, treated patients (mITT, N=17) were compared against an external natural-history cohort (N=27). Treated children showed a 23.5-point higher Bayley-III Cognitive raw score (p<0.0001) over the study period, which became the basis for full approval.

External controls drawn from natural-history data have underpinned other rare-disease gene therapy approvals, including Zolgensma and Skysona, where randomized designs were not practical. Their reliability depends on systematic data collection, meaningful endpoints, and appropriate patient matching. We have written before about the role of natural-history studies as external controls in rare-disease R&D, and FAYUVI is a clear case of that evidence type carrying a registrational decision.

The regulatory context reinforces the pattern. Reporting on 2026 rare-disease decisions counts more than 35 orphan drug approvals and label expansions, several cleared ahead of target dates. In February 2026 the FDA introduced a framework and draft guidance for individualized and ultra-rare therapies that signals openness to natural history and surrogate endpoints where conventional trials are infeasible. The delay before this approval had a specific cause: the original application drew a Complete Response Letter in July 2025 over manufacturing (CMC) issues, not clinical data. The science and the evidence held; the constraints sat elsewhere.

The constraint is shifting from molecule to identification

For most of the last decade, the hard problem in rare-disease gene therapy was scientific and manufacturing capability, whether a vector could be engineered, produced, and shown to work. FAYUVI, whose vector originated at Nationwide Children's Hospital more than a decade ago, shows that path can now be completed. As approvals accelerate, the binding constraint moves downstream, to whether the right patients can be found, genetically confirmed, and followed in time to act on a therapy that only works within a narrow window.

That is a systems problem, and it compounds in ultra-rare disease. With only 3,000 to 5,000 patients across accessible geographies and a benefit that erodes as neurodegeneration advances, a program cannot treat a child it never identifies, and it cannot enroll one it cannot confirm. Recruitment failures in these programs begin well before a site opens, in how eligible patients are located and routed, and the practical work of reaching a dispersed rare-disease population is where timelines are won or lost. Genetic confirmation is part of the same chain: an SGSH-defined diagnosis is what separates a suspected case from an eligible, treatable one, which is why accessible DNA testing sits on the critical path rather than to one side of it.

The natural history cohort that supported this approval points to the second half of the argument. Longitudinal data on untreated patients is both the comparator that makes an external-control approval possible and an asset that a well-designed identification and engagement system produces as a byproduct. Finding and characterizing patients early, then staying connected to them, generates the evidence that the next program will need.

What to watch next

Three questions follow this decision, and each is operational rather than scientific.

• Identification before decline. Because eligibility depends on preserved neurodevelopmental function, the value of an approved therapy is capped by how early children are found and confirmed. Programs that treat identification and genetic confirmation as an afterthought will leave benefit unrealized regardless of the molecule.
• Follow-up as durable evidence. FAYUVI's data already runs toward eight years, and one-time therapies carry long post-treatment monitoring obligations. That long-term follow-up compounds into a lasting evidence asset when it is captured continuously rather than reconstructed later.
• Reusable external controls. As the FDA leans further on natural history, the quality and portability of that data becomes a shared bottleneck. Whether the field builds it once and reuses it will shape how quickly the next ultra-rare program reaches a decision.

The approval of a first therapy for Sanfilippo Type A closes a long scientific chapter. The chapter it opens is about infrastructure: the ability to identify, confirm, and follow small, dispersed patient populations before their window to benefit closes.

To discuss how this may apply to your specific program, get in touch.